Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5080-5084

  Abdi, Muna H ^a   Beswick, Paul J ^a   Billinton, Andy ^a   Chambers, Laura J ^a   Charlton, Andrew ^a   Collins, Sue D ^a   Collis, Katharine L ^a   Dean, David K ^a   Fonfria, Elena ^a   Gleave, Robert J ^a   Lejeune, Clarisse L ^a   Livermore, David G ^a   Medhurst, Stephen J ^a   Michel, Anton D ^a   Moses, Andrew P ^a   Page, Lee ^a   Patel, Sadhana ^a   Roman, Shilina A ^a   Senger, Stefan ^a   Slingsby, Brian ^a   Steadman, Jon G A ^a   Stevens, Alexander J ^a   Walter, Daryl S ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antagonist; P2X7; Pain; SAR

Indexed keywords

(1H PYRAZOL 4 YL)ACETAMIDE DERIVATIVE; ACETAMIDE DERIVATIVE; AMIDE; CELECOXIB; GABAPENTIN; N [(2,4 DICHLOROPHENYL)METHYL] 2 (3,5 DIMETHYL 1H PYRAZOL 4 YL)ACETAMIDE; N ETHYL PRYROGLUTAMIDE DERIVATIVE; PURINERGIC P2X7 RECEPTOR; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VIVO STUDY; NEUROPATHIC PAIN; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; DRUG DISCOVERY; MODELS, MOLECULAR; PURINERGIC P2 RECEPTOR ANTAGONISTS; PYRROLIDONECARBOXYLIC ACID; RECEPTORS, PURINERGIC P2X7; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 77955653157     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.033     Document Type: Article

References (34)

1. G. Collo, S. Neidhart, E. Kawashima, M. Kosco-Vibois, R.A. North, and G. Buell Neuropharmacology 36 1997 1277
2. F. DiVirgilio, V. Vishwanath, and D. Ferrari M.P. Abbraccio, M. Williams, Handbook of Experimental Pharmacology Vol. 151 2001 Springer 355 373
3. H.P. Buisman, T.H. Steinberg, J. Fischbarg, S.C. Silverstein, S.A. Vogelzang, C. Ince, D.L. Ypey, and P.C. Leijh Proc. Natl. Acad. Sci. U.S.A. 85 1988 7988
4. D. Ferrari, C. Pizzirani, E. Adinolfi, R.M. Lemoli, A. Curti, M. Idzko, E. Panther, and F. Di Virgilio J. Immunol. 176 2006 3877
5. D. Fields, and G. Burnstock Nat. Rev. Neurosci. 7 2006 423
6. I.P. Chessel, J.P. Hatcher, C. Bountra, A.D. Michel, J.P. Hughes, P. Green, J. Egerton, M. Murfin, J. Richardson, W.L. Peck, C.B.A. Grahames, M.A. Casula, Y. Yiangou, R. Birch, P. Anand, and G.N. Buell Pain 114 2005 386
7. P.M. Honore, D. Donnelly-Roberts, M. Namovic, G. Hsieh, C. Zhu, J. Mikusa, G. Hernandez, C. Zhong, D.M. Gauvin, P. Chandran, R. Harris, A.P. Medrano, W. Carroll, K. Marsh, J.P. Sullivan, C.R. Faltynek, and M.F. Jarvis J. Pharmacol. Exp. Ther. 319 2006 1376
8. D.C. Broom, D.J. Matson, E. Bradshaw, M.E. Buck, R. Meade, S. Coombs, M. Matchett, K.K. Ford, W. Yu, J. Yuan, S.H. Sun, R. Ochoa, J.E. Krause, D.J. Wustrow, and D.N. Cortright J. Pharmacol. Exp. Ther. 327 2008 620
9. A. Perez-Medrano, D.L. Donnelly-Roberts, P. Honore, G.C. Hsieh, M.T. Namovic, S. Peddi, Q. Shuai, Y. Wang, C.R. Faltynek, M.F. Jarvis, and W.A. Carroll J. Med. Chem. 52 2009 3366
10. D.W. Nelson, R.J. Gregg, M.E. Kort, A. Perez-Medrano, E.A. Voight, Y. Wang, G. Grayson, M.T. Namovic, D.L. Donnelly-Roberts, W. Niforatos, P. Honore, M.F. Jarvis, C.R. Faltynek, and W.A. Carroll J. Med. Chem. 49 2006 3659
11. I.B. McInnes, N.J. Snell, J.H. Perrett, H. Parmar, M.M. Wang, and C. Astbury Arthritis Rheum. [71st Annu Sci Meet Am Coll Rheumatol (Nov 6-11, Boston) 2007] 56 2007 Abst 2085
12. ClinicalTrial.gov Identifier: NCT00628095.
13. L.J. Chambers, A.J. Stevens, A.P. Moses, A.D. Michel, B. Slingsby, D.S. Walter, D.J. Davies, D.J. Livermore, E. Fonfria, E.H. Demont, M. Vimal, P.J. Theobald, P.J. Beswick, R.J. Gleave, S.A. Roman, S. Senger, and S. Roomans Bioorg. Med. Chem. Lett. 20 2010 3161
14. P.J. Beswick, A. Billinton, L.J. Chambers, D.K. Dean, E. Fonfria, R.J. Gleave, S.J. Medhurst, A.D. Michel, A.P. Moses, S. Patel, S.A. Roman, S. Roomans, S. Senger, A.J. Stevens, and D.S. Walter Bioorg. Med. Chem. Lett. 20 2010 4653
15. max values of 100%. Full details of the assay protocol can be found in patent application WO 2007 141267 A1.
16. S.E. Clarke, and P. Jeffrey Xenobiotica 31 2001 591
17. Calculated log D values were obtained using ACD Labs software v8.0.
18. C. Abad-Zapatero Expert Opin. Drug Discovery 2 2007 469
19. P.D. Leeson, and B. Springthorpe Nat. Rev. Drug Disc. 6 2007 881
20. The same concept was independently proposed by researchers at Pfizer and termed lipE. T. Ryckmans, M.P. Edwards, V.A. Horne, A. Monica Correia, D.R. Owen, L.R. Thompson, I. Tran, M.F. Tutt, and T. Young Bioorg. Med. Chem. Lett. 15 2009 4406
21. M.J. Iadarola, J. Douglass, O. Civelli, and J.R. Naranjo Brain Res. 455 1988 205
22. C.H. Hay, M.A. Trevethick, A. Wheeldon, J.S. Browers, and J.S. De Belleroche Neuroscience 78 1997 843
23. A.W. Wilson, S.J. Medhurst, C.I. Dixon, N.C. Bontoft, L.A. Winyard, K.T. Brackenborough, J. De Alba, C.J. Clarke, M.J. Gunthorpe, G.A. Hicks, C. Bountra, D.S. McQueen, and I.P. Chessell Eur. J. Pain 10 2006 537
24. 50 of greater than two- to threefold was considered to be significant and, depending on the baseline degree of inhibition, to potentially represent a developability risk.
25. The overlay was generated using the software FLO (Thistlesoft, Colebrook, CT06021, USA).
26. 24 and annotated with simple calculated properties (e.g., molecular weight, hydrogen-bond donor and acceptor counts).
27. G. Harper, G.S. Bravi, S.D. Pickett, J. Hussain, and D.V.S. Green J. Chem. Inf. Comput. Sci. 446 2004 2145
28. G. Schneider, W. Neidhart, T. Giller, and G. Schmid Angew. Chem., Int. Ed. 38 1999 2894
29. D. Horvath A. Varnek, A. Tropsha, Chemoinformatics Approaches to Virtual Screening 2008 Royal Society of Chemistry Cambridge 44 72
30. Also see WO 2008/003697A1 for additional synthetic details.
31. http://www.cerep.fr.
32. FeSSIF: Fed-state-simulated intestinal fluid. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J.B. Dressman Pharm. Res. 15 1998 698
33. All experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986 under Project Licence as well as under the review and approval of the GlaxoSmithKline Procedures Review Panel. GlaxoSmithKline safety regulations were adhered to at all times.
34. G.J. Bennett, and Y.K. Xie Pain 50 1988 355